KOCA, S. S. Et Al. 2021. Disease Duration and HLA-B27 Positivity Alter Longterm Retention Rate of Certolizumab Pegol in Patients With Psoriatic Arthritis. European Congress of Rheumatology (EULAR) 2021 , (England), 1317.

KOCA, S. S., PEHLİVAN, Y., AKAR, S., ŞENEL, S., KARADENİZ, H., SOYSAL GÜNDÜZ, Ö., ... YAZICI, A.(2021). Disease Duration and HLA-B27 Positivity Alter Longterm Retention Rate of Certolizumab Pegol in Patients With Psoriatic Arthritis . European Congress of Rheumatology (EULAR) 2021 (pp.1317). , England

KOCA, SÜLEYMAN Et Al. "Disease Duration and HLA-B27 Positivity Alter Longterm Retention Rate of Certolizumab Pegol in Patients With Psoriatic Arthritis," European Congress of Rheumatology (EULAR) 2021, England, 2021

KOCA, SÜLEYMAN S. Et Al. "Disease Duration and HLA-B27 Positivity Alter Longterm Retention Rate of Certolizumab Pegol in Patients With Psoriatic Arthritis." European Congress of Rheumatology (EULAR) 2021 , England, pp.1317, 2021

KOCA, S. S. Et Al. (2021) . "Disease Duration and HLA-B27 Positivity Alter Longterm Retention Rate of Certolizumab Pegol in Patients With Psoriatic Arthritis." European Congress of Rheumatology (EULAR) 2021 , England, p.1317.

@conferencepaper{conferencepaper, author={SÜLEYMAN SERDAR KOCA Et Al. }, title={Disease Duration and HLA-B27 Positivity Alter Longterm Retention Rate of Certolizumab Pegol in Patients With Psoriatic Arthritis}, congress name={European Congress of Rheumatology (EULAR) 2021}, city={}, country={England}, year={2021}, pages={1317} }